Impact of patient cost sharing on multiple sclerosis treatment

American Journal of Pharmacy Benefits

Volumn 4, Issue 6, 2012, Pages

  Palmer, Liisa ^a   Abouzaid, Safiya ^b   Shi, Nianwen ^a   Fowler, Robert ^a   Lenhart, Greg ^a   Dastani, Homa ^b   Kim, Edward ^b  

^a IBM WATSON HEALTH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG COST; FEMALE; HAZARD RATIO; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PROBABILITY; REIMBURSEMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

EID: 84869773106     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. National Multiple Sclerosis Society. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx. National Multiple Sclerosis Society website. Published 2011. Accessed October 21, 2011
2. National Multiple Sclerosis Society. Expert Opinion Paper-Disease Management Consensus Statement. http://www.nationalmssociety.org/for-professionals/health-care-professionals/publications/expert-opinion-papers/index.aspx. Published 2008. Accessed October 20, 2011.
3. Margolis JM, Fowler R, Johnson BH, Kassed CA, Kahler K. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol. 2011;11:122.
4. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89-100.
5. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28(1):51-61.
6. Campbell RS, Patel V, Gleeson M, Calimlim B, Zagari M, Curkendall SM. Out-of-pocket health care expenditures and expenditure caps in an insured population with chronic conditions. Am J Pharm Ben. 2011;3(2):98-105.
7. Ozminkowski RJ, Marder WD, Hawkins K, et al. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clinical Therapeutics. 2004;26(8):1341-1354.
8. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-658.
9. Dor A, Lage MJ, Tarrants ML, Castelli-Haley J. Cost sharing, benefit design, and adherence: the case of multiple sclerosis. Adv Health Econ Health Serv Res. 2010;22:175-193.
10. Express Scripts, Inc. Factors predicting patient compliance with specialty drug therapy for multiple sclerosis, inflammatory conditions and hepatitis C. http://www.express-scripts.com/research/studies/pharmacybenefitresearchspecialtypharmacyservices/.Published October 2006. Accessed October 2, 2011.
11. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
12. Solomon MD, Goldman DP, Joyce GF, Escarce JJ. Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med. 2009;169(8):740-748; discussion 748-749.
13. Gibson TB, Jing Y, Kim E, et al. Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. Manag Care. 2010;19(8):40-47.
14. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116. E23